Fulcrum Therapeutics(FULC) - 2023 Q4 - Annual Report

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. Washington, D.C. 20549 (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 26 Landsdowne Street UNITED STATES SECURITIES AND EX ...